Dr. Clement Adebamowo Recognized for Research in Challenging Populations and Settings
Clement A. Adebamowo, BM, ChB, ScD, FWACS, FACS, Associate Director of Population Science at the Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine (UMSOM), and Professor of Epidemiology and Public Health, Institute of Human Virology, has been named a 2018 Fellow of the American Society of Clinical Oncology (ASCO).
Dr. Adebamowo will be honored at the opening session of the ASCO annual meeting on June 2, 2018 in Chicago. ASCO is the world's leading professional organization for physicians and oncology professionals caring for people with cancer. ASCO Fellows are awarded this prestigious award in recognition for their extraordinary volunteer service, dedication, and commitment to the clinical oncology association.
“Dr. Adebamowo is an extremely talented international researcher with a passion to develop quality, international clinical research studies and training opportunities,” said Kevin J. Cullen, MD, the Marlene and Stewart Greenebaum Distinguished Professor of Oncology and Director, Marlene and Stewart Greenebaum Comprehensive Cancer Center. “His impressive track record in cancer research in complex and challenging populations and settings truly makes him a leader in the oncology field and worthy of this special award,” said Jay Magaziner, PhD, MSHyg, Department Chair of Epidemiology and Public Health.
Dr. Adebamowo received his Bachelor’s degree in Surgery and Medicine with honors from the University of Jos, Nigeria and his postgraduate surgical training at the University College Hospital, lbadan Nigeria. Upon graduation, he joined the Department of Surgery as a Lecturer 1 and advanced to Professor of Surgery at the University of lbadan, Nigeria. In 2004 he received his Sc.D. in Nutritional Epidemiology with a minor in Biostatistics from Harvard University. During his medical training and subsequent work he received multiple travel grants and was a Guest Scholar of the American College of Surgeons and the American Society of Clinical Oncology. In 2009, he joined the Institute of Human Virology, Department of Epidemiology and Prevention, Division of Cancer Epidemiology, and the Population Research Program of the University of Maryland Marlene and Stewart Greenebaum Cancer Center as an Associate Professor. In 2013 he was promoted to Professor and in 2015 he became the Associate Director of Population Science, Greenebaum Comprehensive Cancer Center.
Dr. Adebamowo has more than 200 peer-reviewed publications and three active NIH grants. His scientific contributions in the area of HPV infection epidemiology, vaginal microenvironment, cervical carcinogenesis, breast cancer, research ethics and viral genomics are highly significant and represented in his frequently cited publications. His studies are one of the few that properly characterize the molecular subtypes of breast cancer in African populations, a critical requirement for application of modern therapeutics and prognostication. Dr. Adebamowo is also identifying barriers to cervical cancer screening and conducting research into different models of delivering HPV DNA-based vaccines in low resource and under-served communities internationally.
“Dr. Adebamowo is an integral part of our viral cancer research team,” said Robert Gallo, MD, The Homer & Martha Gudelsky Distinguished Professor in Medicine and Director, Institute of Human Virology. “He has been laser-focused on ensuring that our viral cancer research progresses from bench to bedside in both the U.S. and Africa. I am extremely pleased that he has received this well-deserved honor.”
“Dr. Adebamowo has provided immense contributions to our cancer research here at the University of Maryland School of Medicine. His international research in low resource and under-served communities truly embodies our mission,” said E. Albert Reece, MD, PhD, MBA, University Executive Vice President of Medical Affairs and the John Z. and Akiko K. Bowers Distinguished Professor and Dean at the University of Maryland School of Medicine.
About the Institute of Human Virology
Formed in 1996 as a partnership between the State of Maryland, the City of Baltimore, the University System of Maryland and the University of Maryland Medical System, IHV is an institute of the University of Maryland School of Medicine and is home to some of the most globally-recognized and world-renowned experts in all of virology. The IHV combines the disciplines of basic research, epidemiology and clinical research in a concerted effort to speed the discovery of diagnostics and therapeutics for a wide variety of chronic and deadly viral and immune disorders - most notably, HIV the virus that causes AIDS. For more information, www.ihv.org and follow us on Twitter @IHVmaryland.
About the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center is a National Cancer Institute-designated Comprehensive Cancer Center in Baltimore. The center is a joint entity of the University of Maryland Medical Center and University of Maryland School of Medicine. It offers a multidisciplinary approach to treating all types of cancer and has an active cancer research program. It is ranked among the top cancer programs in the nation by U.S. News & World Report. www.umgccc.org.
About the University of Maryland School of Medicine
Commemorating its 210th Anniversary, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States. It continues today as one of the fastest growing, top-tier biomedical research enterprises in the world -- with 43 academic departments, centers, institutes, and programs; and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academy of Medicine and the National Academy of Sciences, and a distinguished recipient of the Albert E. Lasker Award in Medical Research. With an operating budget of more than $1 billion, the School of Medicine works closely in partnership with the University of Maryland Medical Center and Medical System to provide research-intensive, academic and clinically-based care for more than 1.2 million patients each year. The School has over 2,500 students, residents, and fellows, and nearly $450 million in extramural funding, with most of its academic departments highly ranked among all medical schools in the nation in research funding. As one of the seven professional schools that make up the University of Maryland Baltimore campus, the School of Medicine has a total workforce of nearly 7,000 individuals. The combined School and Medical System (“University of Maryland Medicine”) has an annual budget of nearly $6 billion and an economic impact in excess of $15 billion on the state and local community. The School of Medicine faculty, which ranks as the 8th-highest public medical school in research productivity, is an innovator in translational medicine, with 600 active patents and 24 start-up companies. The School works locally, nationally, and globally, with research and treatment facilities in 36 countries around the world. Visit medschool.umaryland.edu/